TSS
PTGX icon

Two Sigma Securities’s Protagonist Therapeutics PTGX Stock Holding History

Two Sigma Securities’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,505
Closed -$212K – 2056
2024
Q4 		$212K Buy
+5,505
New +$240K 0.03% 940
2022
Q3 		– Sell
-12,540
Closed -$99K – 2992
2022
Q2 		$99K Buy
+12,540
New +$152K ﹤0.01% 1755

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Securities's PTGX Position: Q1 2025 in Review

Two Sigma Securities sold out of Protagonist Therapeutics (PTGX) in Q1 2025, closing a stake of 5,505 shares — an estimated $212K sold.

Two Sigma Securities first reported a position in PTGX in Q2 2022 and held it in 2 quarters. The position peaked at $212K in Q4 2024. 275 funds tracked by Wall St. Rank hold PTGX as of Q1 2025.

  • Two Sigma Securities reported no remaining Protagonist Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Two Sigma Securities sold 5,505 Protagonist Therapeutics shares in Q1 2025, an estimated $212K.
  • Two Sigma Securities first reported a position in Protagonist Therapeutics in Q2 2022 and held it in 2 quarters.
  • Two Sigma Securities's Protagonist Therapeutics position peaked at $212K in Q4 2024.
  • 275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2025.

Based on Two Sigma Securities's 13F filing for Q1 2025, filed 15 May 2025.